FINWIRES · TerminalLIVE
FINWIRES

Hon Hai, Bull to Develop AI Infrastructure in Europe

By

Hon Hai Precision Industry (TPE:2317), also known as Foxconn, formed a strategic partnership with French high-performance computing firm Bull to develop artificial intelligence infrastructure in Europe.

Under the deal, Bull will lead AI system design and market development, while Foxconn will handle manufacturing and supply chain support, accoridng to a Monday press release.

The companies said production and initial testing will take place at Foxconn's facility in the Czech Republic, while final assembly, integration, and validation will be completed in France.

The partnership aims to accelerate deployment of AI infrastructure across Europe by combining Bull's system expertise with Foxconn's manufacturing capabilities.

Related Articles

Asia

Western Superconducting Technologies Subsidiary to Launch IPO in Beijing

Western Superconducting Technologies (SHA:688122) subsidiary Xi'an Juneng Superconducting Magnet Technology is looking to launch an IPO on the Beijing Stock Exchange, according to a Tuesday filing with the Shenzhen bourse.Juneng Magnet is looking to issue 25 million shares, with an overallotment option for up to 3.8 million shares.The subsidiary will use the proceeds, set at 301.9 million yuan, to fund its superconducting magnet production and research center projects.

$SHA:688122
Asia

Changchun High-Tech Industry Gets US FDA Nod for Autoimmune Disease Drug Trial

Changchun High-Tech Industry (SHE:000661) subsidiary GeneScience received the approval of the U.S. Food and Drug Administration to start clinical trials in the U.S. for GenSci136.The drug is indicated for autoimmune disease myasthenia gravis, according to a Tuesday filing with the Shenzhen bourse.Shares of the drug manufacturer closed 2% lower Tuesday.

$SHE:000661
Asia

Changchun High-Tech Industry Gets US FDA Nod for Cancer Drug Trial

Changchun High-Tech Industry (SHE:000661) subsidiary GeneScience received approval of the U.S. Food and Drug Administration to start clinical trials in the U.S. for GenSci145 tablets.The drug is indicated for locally advanced or metastatic solid tumors with PIK3CA mutations, which occur in 30% to 40% of breast cancers, according to a Tuesday filing with the Shenzhen bourse.Shares of the drug manufacturer closed 2% lower Tuesday.

$SHE:000661